Meropenem and continuous renal replacement therapy: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1294-1304

  Isla, Arantxazu ^a   Maynar, Javier ^b   Sánchez Izquierdo, José Ángel ^c   Gascón, Alicia R ^a   Arzuaga, Alazne ^a   Corral, Esther ^b   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Continuous renal replacement therapies; Critically ill; Meropenem; Pharmacokinetics

Indexed keywords

CREATININE; MEROPENEM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; STATISTICAL SIGNIFICANCE;

ACRYLIC RESINS; ACRYLONITRILE; ADULT; AGED; AGED, 80 AND OVER; ALKANESULFONATES; ANTI-BACTERIAL AGENTS; FEMALE; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; KIDNEY DISEASES; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PERMEABILITY; POLYMERS; SULFONES; THIENAMYCINS;

EID: 27244460641     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280583     Document Type: Article

References (41)

1. Wiseman LR, Wagstaff AAJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50:73-101.
2. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59:653-680.
3. Burman LA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991;27:219-224.
4. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother. 1995;36(SupplA):35-41.
5. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24(SupplA):311-320.
6. Moon YSK, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis. 1997;24(Suppl2):249-255.
7. Mouton JW, van der Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28:275-286.
8. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36:2794-2798.
9. Talhammer F, Hörl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapies. Clin Pharmacokinet. 2000;39:271-279.
10. Lovering AM, Vickery CJ, Leaper D, et al. The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J Antimicrob Chemother. 1995;36:165-172.
11. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Óqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36:1532-1537.
12. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-492.
13. Joos B, Schimidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous veno-venous haemofiltration. Nephrol Dial Transplant. 1996:11:1582-1585.
14. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1998;42:2417-2420.
15. Krueguer WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother. 1998;42:2421-2424.
16. Meyer MM, Munar MY, Kohlhepp SJ, Bryant RE. Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kid Dis. 1999;33:790-795.
17. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65:50-57.
18. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632-637.
19. Ververs TFT, van Dijk A, Vinks SATMM, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000;28:3412-3416.
20. Valtonen M, Tiula E, Backman JT, Neuvonen PJ. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000;45:701-704.
21. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Pharmacology. 2003;49:280-286.
22. Robatel C, Decosterd LA, Biollaz J, Exkert P, Schaller MD, Buclin Y. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003;43:1329-1340.
23. Sánchez-Izquierdo Riera JA, Alted E, Lozano MJ, Ambros A, Caballero R. Influence of continuous hemofiltration on the hemodynamics of trauma patients. Surgery. 1997;122:902-908.
24. Journois D, Israel-Biet D, Pouard P, et al. High-volume, zero balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology. 1996;85:965-976.
25. Oudemans-van Straaten HM, Bosnian RJ, van der Spoel JI, Zandstra DF. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med. 1999;25:814-821.
26. Honoré PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28:3581-3587.
27. Wuyts B, Bernard D, Van Den Noortgate N, et al. Reevaluation of formulas for predicting creatinine clearance in adults and children, usingcompensated creatinine methods. Clin Chem. 2003;49:1011-1014.
28. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation: a revisit with a decade of progress. Workshop/Conference Report. Pharm Res. 2000;17:1551-1557.
29. Food and Drug Administration. Guidance for industry: bioanalytical methods validation for human studies. Rockville, Md: Center for Drug Evaluation and Research; 1998.
30. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs. 1985;8:307-312.
31. Bauer LA, Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983;72:978-979.
32. Lee CC, Marbury TC. Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clin Pharm. 1984;9:42-66.
33. Kroh UF. Drug administration in critically ill patients with acute renal failure. New Horiz. 1995;3:748-759.
34. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol. 1991;93:110-116.
35. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther. 2005;27:599-608.
36. Beck LL, O'Keefe HJ. The challenges of CRRT delivery following a hospital merger. The 10th International Conference on Continuous Renal Replacement Therapies (CRRT). Abstracts. Blood Purif. 2005;23:149-174.
37. Arzuaga A, Maynar J, Gascon AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45:168-176.
38. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous infusion for critically ill trauma patients. Am J Surg. 2000;179:436-440.
39. Hyatt JM, McKinnon S, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143-160.
40. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89-93.
41. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. 14th informational supplement. NCCLS document M100-S14. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2004.